Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Adoptive Cell Therapy Across Cancer Diagnoses
- Conditions
- Cancer
- Interventions
- Biological: Autologous tumor-infiltrating lymphocytesDrug: IpilimumabDrug: NivolumabDrug: proleukinDrug: CyclophosphamideDrug: Fludara
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 25
- Registration Number
- NCT03296137
- Locations
- 🇩🇰
Center for Cancer immune Therapy (CCIT), Dept. of Hematology and dept. of Oncology, Copenhagen, Denmark
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
- Conditions
- Metastatic Ovarian Cancer
- Interventions
- Drug: CyclophosphamideDrug: FludarabineBiological: TIL infusionDrug: Interleukin-2Drug: IpilimumabDrug: Nivolumab
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Inge Marie Svane
- Target Recruit Count
- 7
- Registration Number
- NCT03287674
- Locations
- 🇩🇰
Center for Cancer Immune Therapy Dept. of Hematology/oncology, Copenhagen, Denmark
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular Lymphoma
- Interventions
- Biological: Chimeric Antigen Receptor T-Cell TherapyDrug: CyclophosphamideOther: Laboratory Biomarker AnalysisProcedure: LeukapheresisDrug: Fludarabine Phosphate
- First Posted Date
- 2017-09-11
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT03277729
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
- Conditions
- Sickle Cell Disease
- Interventions
- Procedure: Haploidentical Bone Marrow TransplantationDrug: HydroxyureaDrug: Rabbit-ATGDrug: ThiotepaDrug: FludarabineDrug: CyclophosphamideRadiation: Total Body IrradiationDrug: Mesna
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 80
- Registration Number
- NCT03263559
- Locations
- 🇺🇸
Texas Children's Hospital (Baylor), Houston, Texas, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸Nicklaus Children's Hospital/University of Miami Children's Hospital, Miami, Florida, United States
Epigenetic Reprogramming in Relapse/Refractory AML
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Target Recruit Count
- 37
- Registration Number
- NCT03263936
- Locations
- 🇺🇸
National Cancer Institute, Pediatric Oncology Branch, Bethesda, Maryland, United States
🇺🇸Children's Hospital Orange County, Orange, California, United States
🇺🇸UCSF School of Medicine, San Francisco, California, United States
Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC
- Conditions
- Graft Versus Host Disease
- Interventions
- Drug: FludarabineDrug: ClofarabineRadiation: Full body irradiationDrug: CyclophosphamideOther: stem cell transplantationOther: nuclear cellsDrug: Thymoglobulin Injectable Product
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2022-07-15
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT03263767
- Locations
- 🇫🇷
Nantes Uh, Nantes, France
CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
- Conditions
- B-cell Acute Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2017-10-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03263208
- Locations
- 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Nivolumab With Chemotherapy in Refractory MDS
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2019-04-05
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 2
- Registration Number
- NCT03259516
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML
- Conditions
- Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- Drug: CrenolanibDrug: CytarabineDrug: Placebo Oral TabletDrug: MitoxantroneDrug: FludarabineDrug: IdarubicinDrug: G-CSF
- First Posted Date
- 2017-08-15
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 322
- Registration Number
- NCT03250338
- Locations
- 🇺🇸
Kansas University, Kansas City, Kansas, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇨🇦University of Alberta, Edmonton, Alberta, Canada
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BusulfanDrug: CyclophosphamideBiological: FilgrastimDrug: FludarabineDrug: Mycophenolate MofetilDrug: SorafenibDrug: Tacrolimus
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 74
- Registration Number
- NCT03247088
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.